Geographical Estimation of the Peptide API Contract Manufacturing Market

An informed capability assessment of different geographies, such as North America, Europe and Asia Pacific, is based on a variety of relevant parameters, such as number of CMOs, number of clinical sites, number of completed / active / planned clinical trials, number of patients enrolled, number of manufacturing facilities, number of CMOs offering manufacturing for API / FDF, number of CMOs having capabilities for clinical / commercial manufacturing, current demand for peptide therapeutics and installed manufacturing capacity in a particular region. Where, North America emerged as the most prominent region as per the above-mentioned parameters. It is worth highlighting that across all the regions, the peptide manufacturing facilities are capable of providing manufacturing services at the clinical scale.

The figure presents the analytical distribution of the above-mentioned parameters in North America.

The "Peptide Therapeutics: Contract API Manufacturing Market, 2020-2030" report features an extensive study of the current market landscape and future opportunities associated with the contract manufacturing of therapeutic peptides. The study also features a detailed analysis of key drivers and trends related to this evolving domain. Amongst other elements, the report includes:

• A detailed review of the overall landscape of companies offering contract services for manufacturing of peptides, along with information on year of establishment, company size, scale of operation (preclinical, clinical and commercial), geographical location of CMO, number and location of their respective facilities, type of peptide synthesis method used, type of peptide modification services offered, peptide purification technology used, and regulatory accreditations / certifications.
• An analysis on the recent developments in the industry, highlighting collaborations, facility expansions, and upcoming peptide synthesis technologies within this domain.
• Informed estimates of the annual commercial and clinical demand for manufacturing peptides for therapeutic use, based on various relevant parameters, such as target patient population, dosing frequency and dose strength.
• A clinical trial analysis of completed, and active studies related to peptide therapeutics that are have been / being / likely to be conducted across various geographies, based on the trial registration year, trial phase, trial recruitment status, therapeutic areas type of sponsor / collaborator, geography and number of patients enrolled.
• An estimate of the overall, installed capacity for manufacturing peptides, based on data reported by industry stakeholders in the public domain; it highlights the distribution of available peptide production capacity across companies of different sizes (small, mid-sized, large and very large firms), scale of operation (clinical and commercial), and key geographical regions (North America, Europe, Asia Pacific).
• A discussion on regulatory guidelines related to peptide manufacturing, highlighting key differences across various geographies, including the US, Europe, Australia, China, India, Japan and South Korea. It also includes details related to the various challenges, related to regulatory scrutiny, faced by peptide manufacturers.
• Elaborate profiles of the key players that offer contract manufacturing services across different geographies, namely North America, Europe and Asia Pacific. Each profile features a brief overview of the company, information on its service portfolio, details related to its manufacturing capabilities and facilities, and an informed future outlook.

Roots Analysis provides market research and consulting in the pharmaceutical industry. Focussed on providing an informed and impartial view on key issues facing the industry, our research is primarily driven by an in-depth analysis.